Contents

Chapter 1: Introduction and outline of the thesis 9

Part 1: Novel treatment approaches

Chapter 2: Time for reappraisal of extracranial treatment options? Synchronous brain metastases from non-small cell lung cancer. 25

Chapter 3: Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small cell lung cancer. 43

Chapter 4: Angiogenesis inhibitors in the treatment of NSCLC. 57

Chapter 5: A multicenter, phase II study of erlotinib and sorafenib in chemotherapy-naïve patients with advanced non-small cell lung cancer. 79

Part 2: Optimising patient selection and treatment monitoring


Chapter 7: Pulmonary toxicity following bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non–small-cell lung cancer 107

Chapter 8: Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity. 117

Chapter 9: CD133+ circulating hematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. 123


Chapter 12:  Summary and discussion

Chapter 13:  Nederlandse samenvatting

Dankwoord / Acknowledgements
CV
List of publications / Conference proceedings